Screener
Ionis Pharmaceuticals IONS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 2,554,764 | 3,034,747 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 166 | 163 |
| Additional paid-in capital | 3,311,837 | 3,145,402 |
| Accumulated other comprehensive loss | (33,897) | (25,281) |
| Accumulated deficit | (2,838,369) | (2,631,195) |
| Total stockholders' equity | 439,737 | 489,089 |
| Total liabilities and stockholders’ equity | $$2,994,501 | 3,523,836 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's retained earnings?
- Ionis Pharmaceuticals (IONS) reported retained earnings of -$2.84B in Q2 2026.
- How has Ionis Pharmaceuticals's retained earnings changed year-over-year?
- Ionis Pharmaceuticals's retained earnings decreased by 24.9% year-over-year, from -$2.27B to -$2.84B.
- What is the long-term trend for Ionis Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's retained earnings has grown at a 16.1% compound annual growth rate (CAGR), from -$1.25B to -$2.63B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Ionis Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude